Summary

Market Lifecycle Stage

The global hyperphosphatemia market is currently in the growth stage of its lifecycle, marked by expanding demand and increasing renal treatment options. This growth is primarily driven by the rising prevalence of chronic kidney disease (CKD), particularly among aging populations, and the growing recognition of hyperphosphatemia as a critical condition in CKD patients, especially those on dialysis. Additionally, regulatory bodies such as the FDA are fast-tracking approvals for new treatments, which is fueling further market expansion. As the number of patients with CKD increases and more treatments enter the market, companies are focusing on enhancing their product portfolios and strengthening market access, both in developed and emerging markets. With these advancements, the market is expected to maintain its growth trajectory, although increased competition, rising generic alternatives, and cost containment pressures may pose challenges as the market matures.

Impact

• Increasing demand for hyperphosphatemia therapies is anticipated to support the growth of the global hyperphosphatemia market during the forecast period 2025-2035.
• The global hyperphosphatemia market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

North America is expected to dominate the global hyperphosphatemia market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global hyperphosphatemia market.

Recent Developments

• Regulatory Activities: In September 2024, Unicycive Therapeutics announced the submission of an NDA to the U.S. FDA for Oxylanthanum Carbonate, intended for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis.
• Regulatory Activities: In July 2024, the U.S. FDA expanded the approval of Velphoro (sucroferric oxyhydroxide) for use in patients as young as 9 years old. The drug, previously approved only for adults, is used to control serum phosphorus levels in patients with chronic kidney disease (CKD) undergoing dialysis.

Demand – Drivers and Limitations

Drivers:
• Rising Prevalence of Chronic Kidney Disease
• Continuous Advancements in Treatment Options

Challenges:
• Economic Barriers in Emerging Markets

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global hyperphosphatemia market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Unicycive Therapeutics, have been involved in the development of therapies for hyperphosphatemia.

Competitive Strategy: Enterprises led by market leaders in the global hyperphosphatemia market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• Kyowa Kirin, Inc.
• Bayer
• Unicycive Therapeutics
• Sanofi
• Shanghai Alebund Pharmaceuticals Limited
• Ardelyx
• Kissei Pharmaceutical Co. Ltd.
• Astellas Pharma Inc.
• Mitsubishi Tanabe Pharma Corporation

ページTOPに戻る

Table of Contents

Executive Summary
Scope of Study
1. Global Hyperphosphatemia Market: Industry Outlook
1.1 Market Overview and Ecosystem
1.2 Market Trends
1.3 Epidemiological Analysis of Hyperphosphatemia
1.3.1 By Region
1.4 Clinical Trials
1.4.1 By Phase
1.4.2 By Sponsor Type
1.5 Regulatory Landscape / Compliance
1.5.1 Legal Requirement and Framework in the U.S.
1.5.2 Legal Requirement and Framework in the E.U.
1.5.3 Legal Requirement and Framework in Asia-Pacific
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. Global Hyperphosphatemia Market, By Region, $Million, 2023-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Hyperphosphatemia Market (by Country)
2.1.2.1.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Hyperphosphatemia Market (by Country)
2.2.2.1.1 U.K.
2.2.2.1.2 Germany
2.2.2.1.3 France
2.2.2.1.4 Italy
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Hyperphosphatemia Market (by Country)
2.3.2.1.1 Japan
3. Global Hyperphosphatemia Market - Competitive Benchmarking and Company Profiles
3.1 Competitive Landscape
3.1.1 Key Strategies and Developments by Company
3.1.1.1 Funding Activities
3.1.1.2 Mergers and Acquisitions
3.1.1.3 Regulatory Approvals
3.1.1.4 Partnerships, Collaborations and Business Expansions
3.1.2 Key Developments Analysis
3.2 Company Profiles
3.2.1 Kyowa Kirin, Inc.
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 Bayer
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Unicycive Therapeutics
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 Sanofi
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Shanghai Alebund Pharmaceuticals Limited
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers/End Users
3.2.5.4 Analyst View
3.2.6 Ardelyx
3.2.6.1 Company Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers/End Users
3.2.6.4 Analyst View
3.2.7 Kissei Pharmaceutical Co. Ltd.
3.2.7.1 Company Overview
3.2.7.2 Product Portfolio
3.2.7.3 Target Customers/End Users
3.2.7.4 Analyst View
3.2.8 Astellas Pharma Inc.
3.2.8.1 Company Overview
3.2.8.2 Product Portfolio
3.2.8.3 Target Customers/End Users
3.2.8.4 Analyst View
3.2.9 Mitsubishi Tanabe Pharma Corporation
3.2.9.1 Company Overview
3.2.9.2 Product Portfolio
3.2.9.3 Target Customers/End Users
3.2.9.4 Analyst View
4. Research Methodology
List of Figures
Figure: Global Hyperphosphatemia Market, Market Overview
Figure: Global Hyperphosphatemia Market, Epidemiological Analysis, U.S.
Figure: Global Hyperphosphatemia Market Coverage
Figure: Global Hyperphosphatemia Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Hyperphosphatemia Market, Competitive Landscape, January 2022-April 2025
List of Tables
Table: Global Hyperphosphatemia Market, Regulatory Scenario
Table: Global Hyperphosphatemia Market Dynamics, Impact Analysis

Press Release